Cargando…

Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases

The transplantation of mesenchymal stem cells (MSCs) for treating neurodegenerative disorders has received growing attention recently because these cells are readily available, easily expanded in culture, and when transplanted, survive for relatively long periods of time. Given that such transplants...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wyse, Robert D., Dunbar, Gary L., Rossignol, Julien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Molecular Diversity Preservation International (MDPI) 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958818/ https://www.ncbi.nlm.nih.gov/pubmed/24463293 http://dx.doi.org/10.3390/ijms15021719

Ejemplares similares

Role of Epigenetics in Stem Cell Proliferation and Differentiation: Implications for Treating Neurodegenerative Diseases
por: Srinageshwar, Bhairavi, et al.
Publicado: (2016)

Use of Genetically Altered Stem Cells for the Treatment of Huntington’s Disease
por: Crane, Andrew T., et al.
Publicado: (2014)

Prion‐like mechanisms in neurodegenerative disease: Implications for Huntington's disease therapy
por: Srinageshwar, Bhairavi, et al.
Publicado: (2020)

Use of Curcumin, a Natural Polyphenol for Targeting Molecular Pathways in Treating Age-Related Neurodegenerative Diseases
por: Maiti, Panchanan, et al.
Publicado: (2018)

Promising Opportunities for Treating Neurodegenerative Diseases with Mesenchymal Stem Cell-Derived Exosomes
por: Guy, Reut, et al.
Publicado: (2020)

Transplantation of mesenchymal stem cells overexpressing interleukin‐10 induces autophagy response and promotes neuroprotection in a rat model of TBI
por: Maiti, Panchanan, et al.
Publicado: (2019)

Induced Pluripotent Stem Cell-Derived Neural Stem Cell Transplantations Reduced Behavioral Deficits and Ameliorated Neuropathological Changes in YAC128 Mouse Model of Huntington's Disease
por: Al-Gharaibeh, Abeer, et al.
Publicado: (2017)

Manipulated Mesenchymal Stem Cells Applications in Neurodegenerative Diseases
por: Sadatpoor, Seyyed omid, et al.
Publicado: (2020)

Use of Polyamidoamine Dendrimers in Brain Diseases
por: Florendo, Maria, et al.
Publicado: (2018)

Dental pulp stem cells for treating neurodegenerative diseases
por: Shamir, Christopher, et al.
Publicado: (2015)

Effects of Passage Number and Differentiation Protocol on the Generation of Dopaminergic Neurons from Rat Bone Marrow-Derived Mesenchymal Stem Cells
por: Shall, Gabrielle, et al.
Publicado: (2018)

Developing biomarkers for neurodegenerative diseases using genetically-modified common marmoset models
por: Tomioka, Ikuo, et al.
Publicado: (2018)

Genetically modified large animal models for investigating neurodegenerative diseases
por: Yang, Weili, et al.
Publicado: (2021)

Current Therapeutic Strategies for Glioblastoma
por: Rossignol, Julien, et al.
Publicado: (2019)

Transplantation of umbilical cord-derived mesenchymal stem cells into the striata of R6/2 mice: behavioral and neuropathological analysis
por: Fink, Kyle D, et al.
Publicado: (2013)

Identification of common genetic modifiers of neurodegenerative diseases from an integrative analysis of diverse genetic screens in model organisms
por: Chen, Xi, et al.
Publicado: (2012)

Transplantation of mesenchymal stem cells genetically engineered to overexpress interleukin-10 promotes alternative inflammatory response in rat model of traumatic brain injury
por: Peruzzaro, S. T., et al.
Publicado: (2019)

CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington’s Disease
por: Kolli, Nivya, et al.
Publicado: (2017)

Correction to: Transplantation of mesenchymal stem cells genetically engineered to overexpress interleukin-10 promotes alternative inflammatory response in rat model of traumatic brain injury
por: Peruzzaro, S. T., et al.
Publicado: (2022)

Reductions in behavioral deficits and neuropathology in the R6/2 mouse model of Huntington’s disease following transplantation of bone-marrow-derived mesenchymal stem cells is dependent on passage number
por: Rossignol, Julien, et al.
Publicado: (2015)

NeuroGeM, a knowledgebase of genetic modifiers in neurodegenerative diseases
por: Na, Dokyun, et al.
Publicado: (2013)

Genetically Engineered Mesenchymal Stem Cells as a Proposed Therapeutic for Huntington’s Disease
por: Olson, Scott D., et al.
Publicado: (2011)

Genetics of neurodegenerative diseases
por: Pulst, Stefan M.
Publicado: (2016)

A novel approach to label bone marrow-derived mesenchymal stem cells with mixed-surface PAMAM dendrimers
por: Munro, Nikolas, et al.
Publicado: (2019)

Silencing of the Mutant Huntingtin Gene through CRISPR-Cas9 Improves the Mitochondrial Biomarkers in an In Vitro Model of Huntington’s Disease
por: Dunbar, Gary L., et al.
Publicado: (2019)

Mesenchymal Stem Cell-Based Therapy for Lysosomal Storage Diseases and Other Neurodegenerative Disorders
por: Issa, Shaza S., et al.
Publicado: (2022)

Increasing β-hexosaminidase A activity using genetically modified mesenchymal stem cells
por: Shaimardanova, Alisa A., et al.
Publicado: (2023)

PAMAM Dendrimer Nanomolecules Utilized as Drug Delivery Systems for Potential Treatment of Glioblastoma: A Systematic Review
por: Fana, Michael, et al.
Publicado: (2020)

Labeling of Disease-Modifying Therapies for Neurodegenerative Disorders
por: Morant, Anne Vinther, et al.
Publicado: (2019)

Recent Advances in the Application of Mesenchymal Stem Cell-Derived Exosomes for Cardiovascular and Neurodegenerative Disease Therapies
por: Yang, Zhimin, et al.
Publicado: (2022)

Extracellular Vesicles from Mesenchymal Stem Cells: Towards Novel Therapeutic Strategies for Neurodegenerative Diseases
por: Turano, Ermanna, et al.
Publicado: (2023)

The Role of Genetically Modified Mesenchymal Stem Cells in Urinary Bladder Regeneration
por: Snow-Lisy, Devon C., et al.
Publicado: (2015)

Genetically Modified Mesenchymal Stromal/Stem Cells: Application in Critical Illness
por: Varkouhi, Amir K., et al.
Publicado: (2020)

Potential advantages of genetically modified mesenchymal stem cells in the treatment of acute and chronic liver diseases
por: Sani, Farnaz, et al.
Publicado: (2023)

Tart Cherry Extract and Omega Fatty Acids Reduce Behavioral Deficits, Gliosis, and Amyloid-Beta Deposition in the 5xFAD Mouse Model of Alzheimer’s Disease
por: Bowers, Zackary, et al.
Publicado: (2021)

Stem cells for the treatment of neurodegenerative diseases
por: Dantuma, Elise, et al.
Publicado: (2010)

Stem Cells for the Treatment of Neurodegenerative Diseases
por: Wu, Yong-Ping, et al.
Publicado: (2010)

In Vivo Assessment of Stem Cells for Treating Neurodegenerative Disease: Current Approaches and Future Prospects
por: Song, Byeong-Wook
Publicado: (2017)

Correction: Bowers et al. Tart Cherry Extract and Omega Fatty Acids Reduce Behavioral Deficits and Gliosis in the 5xFAD Mouse Model of Alzheimer’s Disease. Brain Sci. 2021, 11, 1423
por: Bowers, Zackary, et al.
Publicado: (2023)

Genetically Modified Mesenchymal Stem Cells: The Next Generation of Stem Cell-Based Therapy for TBI
por: Shahror, Rami Ahmad, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tlb77i5h7mitr8bv54v81fc5gs